Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971483 | 0.69 | KDM4E (0.37) | ALDH1A1TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL470176 | 0.66 | KEAP1 (0.38) | ALDH1A1POLBTAAR1HTR1ADRD2 | |
| SCHEMBL1858414 | 0.65 | TAAR1 (0.36) | TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL6422332 | 0.65 | — | — | |
| SCHEMBL21505763 | 0.65 | TAAR1 (0.35) | ALDH1A1POLBTAAR1HTR1ADRD2 | |
| SCHEMBL27386493 | 0.65 | KEAP1 (0.39) | ALDH1A1TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL16742556 | 0.59 | TAAR1 (0.39) | TAAR1HTR1ADRD2HTR7 | |
| SCHEMBL11496788 | 0.58 | CHRM2 (0.36) | ALDH1A1POLBTAAR1HTR1ADRD2 | |
| SCHEMBL3101559 | 0.58 | ALDH1A1 (0.40) | ALDH1A1POLBTAAR1HTR1ADRD2 | |
| SCHEMBL18825907 | 0.58 | FNTA (0.33) | ALDH1A1POLBTAAR1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | ALDH1A1 476/4885POLB 4498/4885TAAR1 1291/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | ALDH1A1 603/4885POLB 3063/4885TAAR1 981/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | ALDH1A1 530/4885POLB 3233/4885TAAR1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.